SETD2 and nonpapillary renal cell carcinoma: Alterations in polybromo 1 (PBRM1), breast cancer early onset (BRCA)‐associated protein 1 (BAP1), SET domain containing 2 (SETD2) and enhancer zeste 2 polycomb repressive complex 2 subunit (EZH2) are closely associated with clinical outcomes in ccRCC patients [15, 16, 17, 18, 19].